Your browser doesn't support javascript.
loading
Development of Spinal Enthesopathies in Adults With X-linked Hypophosphatemia.
Herrou, Julia; Fechtenbaum, Jacques; Rothenbuhler, Anya; Kamenický, Peter; Roux, Christian; Linglart, Agnès; Briot, Karine.
Afiliação
  • Herrou J; Department of Rheumatology, INSERM UMR 1153, Université de Paris-Cité, APHP Centre, Cochin Hospital, 75014 Paris, France.
  • Fechtenbaum J; Department of Rheumatology, APHP Centre, Cochin Hospital, 75014 Paris, France.
  • Rothenbuhler A; Department of Rheumatology, APHP Centre, Cochin Hospital, 75014 Paris, France.
  • Kamenický P; Reference Center for Rare Diseases of the Calcium and Phosphate Metabolism, OSCAR Network for Rare Bone and Calcium Phosphate Disorders, Paris, France.
  • Roux C; Department of Endocrinology and Diabetes for Children, APHP, Bicêtre Paris Saclay Hospital, 94270 Le Kremlin Bicêtre, France.
  • Linglart A; APHP, Plateforme d'expertise Paris Saclay maladies rares, Bicêtre Paris Saclay Hospital, 94270 Le Kremlin Bicêtre, France.
  • Briot K; Reference Center for Rare Diseases of the Calcium and Phosphate Metabolism, OSCAR Network for Rare Bone and Calcium Phosphate Disorders, Paris, France.
J Clin Endocrinol Metab ; 108(12): e1524-e1531, 2023 Nov 17.
Article em En | MEDLINE | ID: mdl-37390471
ABSTRACT
CONTEXT Musculoskeletal complications are the main manifestations in adults with X-linked hypophosphatemia (XLH). Enthesopathy significantly impairs quality of life.

OBJECTIVE:

To identify the risk factors associated with the development and progression of spinal enthesopathies in adults with XLH. DESIGN AND

SETTING:

We conducted a retrospective study in the French Reference Center for Rare Diseases of the Calcium and Phosphate Metabolism. PATIENTS Adults XLH patients with 2 EOS® imaging performed at least 2 years apart at the same center between June 2011 and March 2022. The progression of enthesopathies was defined as a new enthesopathy at least 1 intervertebral level in patients with or without presence of enthesopathy at baseline. MAIN OUTCOME

MEASURES:

Demographic, treatment, PHEX mutation with the progression of enthesopathies.

RESULTS:

Fifty-one patients (66.7% of women, mean age 42.1 ± 13.4 years) underwent 2 EOS imaging with an average interval of 5.7 (± 2.31) years.Progression of spinal enthesopathies was observed in 27 (52.9%) patients. In univariate analysis, patients with a progression of spinal enthesopathies were significantly older (P < .0005), were significantly older at treatment initiation (P = .02), presented with dental complications (P = .03), received less frequently treatment during childhood with phosphate and/or vitamin D analogs (P = .06), and presented more frequently with hip osteoarthritis (P = .002) at baseline. In multivariate analysis, none of these factors was associated with a progression of spinal enthesopathies.

CONCLUSION:

This study confirms the high proportion of patients with a progression of spinal enthesopathies. Age seems to be the main factor associated with progression.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Hipofosfatemia / Raquitismo Hipofosfatêmico Familiar / Entesopatia Tipo de estudo: Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Adult / Female / Humans / Middle aged Idioma: En Ano de publicação: 2023 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Hipofosfatemia / Raquitismo Hipofosfatêmico Familiar / Entesopatia Tipo de estudo: Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Adult / Female / Humans / Middle aged Idioma: En Ano de publicação: 2023 Tipo de documento: Article